

RESEARCH ARTICLE

Persistent hypertension among postpartum women with comorbid HIV and preeclampsia in Zambia

Moses Mukosha^{1‡a*}, Abigail Hatcher^{1‡b}, Mwansa Ketty Lubeya^{2‡}, Innocent Maposa^{3‡}, Benjamin H. Chi^{4‡}, Wilbroad Mutale^{5‡}

1 Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, **2** Department of Obstetrics and Gynaecology, University of Zambia, Lusaka, Zambia, **3** Department of Global Health, Division of Epidemiology & Biostatistics, Stellenbosch University, Cape Town, South Africa, **4** Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America, **5** Department of Health Policy and Management, University of Zambia, Lusaka, Zambia


☞ These authors contributed equally to this work.

‡a Current address: Department of Pharmacy, University of Zambia, Lusaka, Zambia

‡b Current address: Department of Health Behavior, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America

‡ MKL and IM also contributed equally to this work.

* mukoshamoses@yahoo.com



OPEN ACCESS

Citation: Mukosha M, Hatcher A, Lubeya MK, Maposa I, Chi BH, Mutale W (2024) Persistent hypertension among postpartum women with comorbid HIV and preeclampsia in Zambia. PLoS ONE 19(9): e0309915. <https://doi.org/10.1371/journal.pone.0309915>

Editor: Theresa Azonima Irinyenikan, University of Medical Sciences Ondo City, NIGERIA

Received: June 10, 2024

Accepted: August 20, 2024

Published: September 4, 2024

Copyright: © 2024 Mukosha et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its [Supporting Information](#) files.

Funding: Trainee support for MM was provided by the UNC-UNZA-Wits Partnership for HIV and Women's Reproductive Health which is funded by the Fogarty International Center (D43 TW010558). The contents of this article are the authors' responsibility and do not necessarily reflect the views of the funders. The funders had no role in the

Abstract

Background

Persistent hypertension is common after preeclampsia and is causally tied to later cardiovascular risks. This study examined whether being HIV-infected and on antiretroviral therapy (ART) is associated with persistent postpartum hypertension among women diagnosed with preeclampsia.

Methods

We conducted a six-month prospective cohort study at Kanyama and Women and Newborn hospitals from January 01, 2022, to June 30, 2023, among 190 women diagnosed with preeclampsia (59 HIV-positive, 131 HIV-negative). Sociodemographic and clinical characteristics were collected at delivery, six weeks, three months and six months after giving birth. Persistent hypertension was diagnosed if a participant presented with elevated blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg and/or taking medication for hypertension at the study visit. We used a generalized estimating equation to describe the relationship between treated HIV and persistent hypertension six months following delivery.

Results

We retained 136 participants (71.6%) to six months postpartum, at a median age of 30 years. Overall, persistent hypertension at six weeks, three months, and six months postpartum was common (37.4%, 17.1% and 16.9%, respectively). Six-week postpartum prevalence was higher in the HIV group than HIV-negative group (54.6% vs 28.8%, $p < 0.001$), with no measurable difference at three months (24.3% vs 13.2%, $p = 0.145$) or six months

study design/conduct, decision to publish, or manuscript preparation.

Competing interests: The authors have declared that no competing interests exist.

(18.2% vs 16.3%, $p = 0.787$). Multivariable analysis demonstrates higher odds (adjusted odds ratio [aOR] = 1.68, 95% CI: 1.09–2.60) of persistent hypertension among the HIV +treatment group than HIV-negative counterparts after accounting for age, body mass index and time since delivery.

Conclusion

We demonstrate an elevated risk of persistent hypertension among postpartum women with comorbid preeclampsia and treated HIV. Peripartum patients in HIV-endemic settings may benefit from timely detection of hypertension and treatment interventions to improve health outcomes.

Introduction

Hypertension is a major cause of premature deaths globally, affecting nearly one in five women [1]. Hypertension is characterized by elevated systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg or taking medication for hypertension [2]. The burden is shared disproportionately in low and middle-income countries (LMICs), where hypertension is estimated between 15% and 54% [3]. Most women in LMICs continue to die from preventable hypertension-related complications, such as stroke and ischaemic heart disease [4, 5]. In sub-Saharan Africa 42% of deaths are attributable to high blood pressure, of which 20% are female deaths [6].

Emerging evidence suggests that women with preeclampsia are at an increased risk of persistent hypertension and other cardiovascular diseases after giving birth and beyond [7–9]. There are many risk factors for persistent hypertension, including increased body mass index, the severity of preeclampsia, parity, and advanced maternal age [10, 11]. Other factors may be HIV and ART, although previous reports have not been conclusive [12, 13]. Small studies of women living with HIV reported a high prevalence of persistent hypertension (85.7% and 83.3%) [8, 14]. One plausible mechanism through which HIV and persistent hypertension could be associated is through the shared inflammation cascade in women recovering from preeclampsia [15–18]. Both HIV and preeclampsia are characterized by increased expression of pro-inflammatory cytokines which are responsible for endothelial dysfunction leading to hypertension [19, 20]. Additionally, there is evidence that suggests that ART regimens (i.e. protease inhibitors) may be associated with hypertension in pregnancy as well [21].

Furthermore, studies done during pregnancy suggest that HIV and ART are associated with worse health outcomes for women with preeclampsia, such as premature births, stillbirths and small for gestational age [22–25]. However, the association between persistent hypertension and HIV after preeclampsia remains unclear. Therefore, to address this gap, we examined whether being HIV-infected and on ART is associated with persistent postpartum hypertension six months after giving birth in women whose pregnancy was complicated by preeclampsia.

Materials and methods

Study design, setting and population

A prospective cohort study was conducted between Jan 01, 2022, and June 30, 2023, at the Women and Newborn Hospital and the Kanyama General Hospital in Lusaka Urban, Zambia.

The two hospitals have obstetricians/gynaecologists and nurse midwives and receive referrals of women with preeclampsia from surrounding clinics. The health services are offered free of user fees. From the two hospitals on average about 24000 pregnant women are seen per year with over 12000 births.

Women diagnosed with preeclampsia were invited to participate after giving birth. Preeclampsia, in this setting, is diagnosed following the American College of Obstetricians and Gynecologists guidelines as a new-onset of hypertension (SBP ≥ 140 mm Hg and/or DBP ≥ 90 mm Hg) after 20 weeks of gestation and the presence of proteinuria or other maternal organ dysfunction [26]. The local hospital obstetrician diagnosed preeclampsia during antenatal clinic visits or at admission for referral cases, and the study staff verified the diagnostic criteria via independent chart reviews.

Antenatal care is offered routinely using the WHO 2016 guidelines and local guidelines. In tertiary and general hospitals, medical doctors are in charge of reviewing clients, while in primary healthcare facilities, midwives offer antenatal care, who then refer women with abnormal blood pressure readings and urinalysis for further evaluation. Women are offered a recommended eight antenatal visits. On each one of these visits, routine urinalysis and blood pressure measurements are taken.

We excluded women with a documented medical history of co-morbidities: diabetes mellitus, essential hypertension or taking antihypertensive medication, chronic renal failure, thyroid disorders and lupus erythematosus. This study has been reported following the Guidelines for Strengthening The Reporting of Observational Studies in Epidemiology (S1 Checklist) [27].

Study procedures

From our prior work at the study site [28], we anticipated low numbers of women with HIV and preeclampsia. Therefore, we consecutively enrolled women living with HIV and enrolled HIV-negative participants using a systematic sampling technique based on average daily hospital deliveries and preeclampsia prevalence we enrolled every third eligible woman as indicated by entrance into the facility log book. At enrollment, we recorded contact information and made appointments for the remaining follow-up visits. Upon discharge from the hospital, participants were invited to return at six weeks, three months and six months postpartum. If there was elevated blood pressure at any visit, a follow-up visit was made 1–2 weeks later to confirm medical records for diagnosis of chronic hypertension. Women diagnosed with chronic hypertension were referred to the outpatient medical clinic for management.

Study outcome

The primary study outcome was the proportion of women with persistent hypertension (Systolic Blood Pressure [SBP] ≥ 140 mmHg and/or Diastolic Blood Pressure [DBP] ≥ 90 mmHg at rest or receiving hypertension treatment) in the six months from delivery [5]. Blood pressure was measured on the day following delivery, six weeks, three months and six months. Research assistants measured blood pressure at least two times 5 minutes apart. For any measurements that differed by at least 10%, then a third measurement was done to confirm the final reading. Blood pressure measurements were taken after five minutes of rest in a seated upright position. We used a validated device for pregnancy and hypertensive pregnancy disorders so that accurate readings are obtained and utilized for clinical decisions [29]. Cuff sizes were made available during measurements based on the patient's arm's size, measured at the upper arm's midpoint.

Study exposures

The primary exposure of interest was HIV-serostatus. Since all pregnant women with HIV in this setting are offered ART (and since treatment uptake was high), the exposure was combined HIV+ART. Based on the Zambian clinical guidelines on HIV testing during pregnancy, all the women presenting to the antenatal clinic are continually tested as a routine standard of care [30]. Therefore, this study used maternal clinical records at enrollment to check for the HIV test results, and for those with missing results, the midwives conducted HIV tests after counselling using standard routine clinical practice guidelines [31, 32]. In addition, women who test positive are initiated on ART regardless of their immune status or clinical stage [32]. Therefore, all the participants in this study who were living with HIV were on ART. Currently, in Zambia, pregnant women are given a fixed combination of Tenofovir, Lamivudine and Dolutegravir as the preferred first-line treatment for HIV infection [33].

A structured questionnaire was offered by a trained nurse to assess socio-demographic characteristics of marital status (unmarried/married), maternal age (age in years from last birthday) and primary school education vs. higher levels of education (none, primary, secondary, tertiary). Additionally, we assessed food insecurity score using the household hunger scale [34] and socio-economic status using a demographic and health survey questionnaire with various economic characteristics (such as the source of drinking water, type of toilet, floor, roof, wall, cooking fuel and material possessions like television, radio etc) [35]. From the demographic and health survey questionnaire, scores were computed from all the 'YES' answers and then categorised into quintiles of wealth index (poorest, poorer, middle, richer, richest). Body Mass Index (BMI) was measured from the participant's weight and height, while gestational age was assessed based on the last menstrual period [31]. We also measured the severity of preeclampsia; mild (hypertension [140/90 to 149/99 mmHg]) moderate (150/100 to 159/109 mmHg) and severe (160/110 mmHg or higher) [36]. Other variables measured were the onset of preeclampsia, i.e., early-onset (less than 34 weeks gestation) and late-onset (more than 34 weeks gestation) [37], adverse pregnancy outcomes i.e., preterm birth (<37 completed weeks gestation) or stillbirth, Contraceptive use (Intrauterine Contraception, hormonal methods, barrier methods and dual methods) and probable anxiety/depression using validated cut points for the Hospital Depression and Anxiety Scale [38]. The scoring of anxiety and depression levels was done from 0 to 21 and categorised as follows; 0–9 no anxiety/depression and 10 or more, anxiety/depression.

Sample size

We assumed the risk of persistent hypertension to be 35.0% in women living with HIV on ART versus 12% in HIV-negative women [14] and estimated that we would require at least 123 women (41 HIV on ART versus 82 HIV negative) to detect a 23% difference in risk of persistent hypertension with over 80% power and an alpha level of 5%. To meet this threshold while accounting for presumed loss to follow-up of over 20%, we enrolled 190 participants.

Data management and analysis

We used both descriptive and analytical methods for statistical analysis. We described the change in hypertension by HIV serostatus using a bar graph to illustrate trends for the study population over time. We used the Pearson Chi-square test to assess the association between HIV and hypertension.

Using a Generalized Estimating Equation for panel data, we examined the effects of HIV and ART on the change in hypertension status (from hypertension to healthy and back to hypertension) over the six-month follow-up. We fitted both unadjusted and adjusted models

with unstructured correlation. In the adjusted model, HIV, age and body mass index were set *a priori* based on the clinical importance. Other covariates were selected based on clinical relevance and statistical significance $p < 0.2$ from the unadjusted model. In the final model interaction between time since delivery and HIV/ART was assessed at a significance level of alpha less than 0.05. The analysis used the intention-to-treat approach.

We used REDCap (Research Electronic Data Capture) electronic data capture tools hosted at the University of the Witwatersrand Johannesburg, South Africa, for data management and Stata (version 17/BE; StataCorp, College Station, Texas, USA) for data analysis. Statistical significance for all tests was set at $p < 0.05$.

Ethical consideration

We obtained ethical approval from the University of Zambia Biomedical Research Ethics Committee (ref: 1785–2021) and the Human Research Ethics Committee (Medical [ref: R14/49]) at the University of Witwatersrand School of Health Sciences South Africa. All participants provided fully written informed consent before enrollment. All information was explained to potential participants using non-technical language, in the participant's preferred language. The confidentiality of all study records was safeguarded to the extent legally possible. All laboratory specimens, reports, study data and administrative forms were de-identified and the link log was stored on a password-protected online / computer database. Follow-up information about participants was collected separately and stored in lockable cupboards by the research assistants. Participants were allowed to discontinue participation and decide that their medical data could not be used in the analysis without repercussions on their medical care.

Inclusivity in global research

Additional information regarding the ethical, cultural, and scientific considerations specific to inclusivity in global research is included in the Supporting Information ([S2 Checklist](#))

Results

Between January 01, 2022, and January 01, 2023, a total of 190 women diagnosed with preeclampsia were enrolled in the study after giving birth, of whom 59 were living with HIV on ART ([Fig 1](#)). During the follow-up period, 2 participants died, 33 were lost to follow-up, and 19 withdrew from the study. Overall, 136 (71.6% retention) participants completed the six-month follow-up: 44 living with HIV on ART and 92 without HIV. During follow-up 23 were diagnosed with chronic hypertension (8 living with HIV on ART and 15 without HIV). Similar socio-demographic characteristics ([S1 Table](#) in [S1 File](#)) were seen among those retained compared to the loss to follow-up.

Characteristics of study participants

[Table 1](#) shows baseline participant characteristics by the HIV serostatus at baseline. The median age was 30 years (interquartile range [IQR]: 27–34), and the majority, 158 (83.2%) were married. The largest proportion, 150 (79.0%), had secondary education, and 114 (60.0%) were in the lower wealth index quintile.

Prevalence of persistent hypertension during follow-up

The prevalence of persistent hypertension during follow-up by HIV serostatus is shown in [Fig 2](#). Of 136 participants, 23 were hypertensive at six months after delivery (16.9%, 95% CI:




Fig 1. Flow of participants in the study.

<https://doi.org/10.1371/journal.pone.0309915.g001>

11.0–24.3). The prevalence at six weeks was higher in the HIV group than HIV-negative group (54.6% vs 28.8%, $p < 0.001$). However, by three months (24.3% vs 13.2%, $p = 0.15$) and six months (18.2% vs 16.3%, $p = 0.787$) statistical differences were no longer observed. Analysis of trends showed a significant reduction in the proportion of participants with persistent hypertension over six months postpartum ($p < 0.001$).

Persistent hypertension at 6 months and participant characteristics

Table 2 shows participant characteristics by the hypertension status. The median age was 29 years (interquartile range [IQR]: 26–34), and the majority, 112 (82.4%) were married, 108 (79.4%) attained at least a secondary level of education and 81 (59.6%) were in the lower quintiles of wealth index. Women with and without hypertension had similar median age but differed in the median body mass index.

Risk factors of persistent hypertension status changes during follow-up

Table 3 shows the crude and adjusted models for risk factors of persistent hypertension status changes from each measurement time point to the other during the six-month follow-up. From the crude model, Individuals with HIV on ART had a 25% increased odds of hypertension compared to those without HIV, however, with a borderline p-value. On the other hand, the factors associated with persistent hypertension were probable depression and anxiety, body parity, severity of preeclampsia and food insecurity score.

Table 1. Baseline sociodemographic and obstetric characteristics of participants by HIV serostatus status.

Variable	Total population n = 190(%)	HIV serostatus		P-value
		Negative, n = 131	Positive, n = 59	
Age in years, median (IQR)	30(27–34)	30(26–34)	31(27–35)	0.421
Marital status				
Unmarried	32(16.8)	23(17.6)	9(15.3)	0.695
Married	158(83.2)	108(82.4)	50(84.8)	
Education				
None/Primary	40(21.1)	20(15.3)	20(33.9)	0.004
Secondary/Tertiary	150(79.0)	111(84.7)	39(66.1)	
Wealth index				
Poorest/poorer/middle	114(60.0)	74(56.5)	40(67.8)	0.141
Richer/richest	76(40.0)	57(43.5)	19(32.2)	
Onset of preeclampsia				
Early (<34 weeks)	93(49.0)	67(51.2)	26(44.1)	0.367
Late (≥34 weeks)	97(51.1)	64(48.9)	33(55.9)	
Severity of preeclampsia				
Severe	15 (7.9)	8(6.1)	7(11.9)	0.243
Mild/Moderate	175(92.1)	123(93.9)	52(88.1)	
Pregnancy outcomes				
Stillbirth	25(13.2)	13(9.9)	12(20.3)	0.026
Preterm birth	33(17.4)	28(21.4)	5(8.5)	
Live/term birth	132(69.5)	90(68.7)	42(71.2)	
Parity median(IQR)	2(1–3)	2(1–3)	2(1–4)	0.070
Contraceptive use				
Other ^a	58(30.5)	32(24.4)	26(44.1)	0.005
Intrauterine/barrier	28(14.7)	25(19.1)	3(5.1)	
Hormonal	104(54.7)	74(56.5)	30(50.9)	
Anxiety and depression				
No	43(22.6)	18(13.7)	25(42.4)	<0.001
Yes	147(77.4)	113(86.3)	34(57.6)	

Abbrev: IQR-interquartile range, ^a(sterilization, lactational amenorrhea, withdrawal, fertility awareness-based methods or dual methods), p-values from Pearson Chi-square test/Fisher's exact test/Wilcoxon Ranksum test

<https://doi.org/10.1371/journal.pone.0309915.t001>

In the multivariable model, HIV on ART, probable depression and anxiety, severity of preeclampsia and parity were significantly associated with changes in hypertension status over time. Compared to HIV-negative, participants living with HIV on ART (adjusted odds ratio [AOR] = 1.68, 95% CI: 1.09–2.60) were more likely to have hypertension during the six months postpartum.

Sensitivity analysis

From the multivariable models with continuous outcomes, HIV on ART had a significant effect on the mean descent in systolic and diastolic blood pressure (S2 Table in [S1 File](#)). On average the mean systolic and diastolic blood pressure was 4.02 and 2.72 units higher among the women living with HIV than HIV-negative women at every time point measured since delivery. There was no evidence to suggest that persistent hypertension among women living with HIV compared to HIV-negative women differ by the time since delivery (S3 Table in [S1 File](#)).

Discussion

In a clinical sample in urban Zambia, 16.9% of postpartum women experienced persistent hypertension six months after giving birth. Those women previously diagnosed with pre-




Fig 2. Prevalence of persistent hypertension and the trends during the follow-up visits.

<https://doi.org/10.1371/journal.pone.0309915.g002>

eclampsia and living with HIV on ART had 1.68-fold higher odds of persistent hypertension than their HIV-negative counterparts. Similarly, participants with increased parity and those who reported probable anxiety and depression had higher odds of persistent hypertension. On the other hand, participants with mild or moderate pre-eclampsia had lower odds of persistent hypertension than those with severe pre-eclampsia.

Persistent hypertension rate was comparable between women living with and without HIV by 6 months postpartum despite the former having higher odds of persistent hypertension at any time point during follow-up. This was corroborated by our results from sensitivity analysis where we noted a similar effect on the mean descent in systolic and diastolic blood pressure. It's unclear about the mechanism behind the observed rates as little is known about HIV and persistent hypertension after preeclampsia in the extant literature. We speculate this could be a mismeasurement of HIV due to the complexities between HIV suppressing immunity alongside immune reconstitution through ART [39–41]. Given that HIV and ART may have complicated pathways depending on the physiological circumstance [42], further studies are warranted to fully elucidate their mechanisms in postpartum women after preeclampsia.

In the general population, some studies have reported persistent hypertension after preeclampsia; though data remains sparse [8, 9, 43]. Few studies have specifically studied HIV/ART and persistent hypertension after preeclampsia and suggested this possible association, but the limited number of participants living with HIV led to unreliable estimates [8, 44]. A recent systematic review and meta-analysis of global data demonstrated that 35% of all HIV-infected adults on ART had hypertension compared to 30% of HIV-uninfected [45]. Furthermore, results from published studies show that ART may alter various metabolic processes, leading to obesity and overweight, all of which are known risk factors for hypertension [46, 47]. Therefore, the present study's findings align with previous findings in the general

Table 2. Participants characteristics at 6 months postpartum visit by persistent hypertension.

Variable	Total population n = 136(%)	Normotensive, n = 113(%)	Hypertensive ^a , n = 23(%)	P-value
HIV serostatus				
Negative	92(67.7)	77(68.1)	15(65.2)	0.785
positive	44(32.4)	36(31.9)	8(34.8)	
Age in years (IQR)	29(26–34)	29(26–33.5)	30(27–35)	0.228
Marital status				
Unmarried	24(17.7)	21(18.6)	3(13.0)	0.765
Married	112(82.4)	92(81.4)	20(87.0)	
Education level				
None/Primary	28(20.6)	24(21.2)	4(17.4)	0.677
Secondary/Tertiary	108(79.4)	89(78.8)	19(82.6)	
Wealth index				
Poorest/poorer/middle	81(59.6)	65(57.5)	16(69.6)	0.283
Richer/richest	55(40.4)	48(42.4)	7(30.4)	
Gestational age at delivery, median(IQR)	33(30–36)	33(30–36)	34(32–36)	0.361
Onset of pre-eclampsia				
Early (<34 weeks)	71(52.2)	59(52.2)	12(52.2)	0.997
Late (≥34 weeks)	65(47.8)	54(47.8)	11(47.8)	
Severity of Pre-eclampsia				
Severe	9(6.6)	5(4.4)	4(17.4)	0.044
Mild/Moderate	127(93.4)	108(95.6)	19(82.6)	
Adverse pregnancy				
Stillbirth	18(13.2)	15(13.3)	3(13.0)	0.706
Preterm birth	26(19.1)	23(20.4)	3(13.0)	
Live/term birth	92(67.7)	75(66.4)	17(73.9)	
Parity median(IQR)	2(1–3)	2(1–3)	3(2–4)	0.009
Contraceptive use				
Other ^b	24(17.8)	22(19.6)	2(8.7)	0.035
Intrauterine/barrier	17(65.7)	17(15.2)	-	
Hormonal	94(69.6)	73(65.2)	21(91.3)	
Body mass index kg/m ² median(IQR)	27.3(24.2–30.4)	27.3(23.8–30.1)	27.7(25.8–30.9)	0.008
Anxiety and depression				
No	81(59.6)	72(63.7)	9(39.1)	0.029
Yes	55(40.4)	41(36.3)	14(60.9)	

Abbrev: IQR-interquartile range

^adefined as elevated systolic blood ≥ 140 mmHg and diastolic blood pressure ≥ 90 mmHg and or taking hypertension medication^b(sterilization, lactational amenorrhea, withdrawal, fertility awareness-based methods or dual methods)p-values from Pearson Chi-square test/Fisher's exact test/Wilcoxon Ranksum test<https://doi.org/10.1371/journal.pone.0309915.t002>

population that HIV/ART are associated with hypertension and other cardiovascular diseases [48, 49]. We speculate that HIV on ART could have an additive effect on preeclampsia, which could potentially be worsening the persistent hypertension in the postpartum period.

The prevalence of persistent hypertension at six months' follow-up is comparable to the regional estimates. The prevalence was higher than that found in Cameroon (14.8%) [50], but lower than in Kenya (44.4%) [51] and Nigeria (62.2%) [9]. The rates in high-income countries average around 10% to 20%. For example, in the United Kingdom, the rates are 13% [52], in the USA 19% [43] and 20.3% in Switzerland, 10.8% [52] in France [53] and 17% in Japan [54]. The differences in study settings, onset, and severity of preeclampsia among studied participants could partly account for the disparity. Additionally, most high-income countries have guidelines on risk reduction for women after preeclampsia.

Participants with mild or moderate preeclampsia were less likely to have persistent hypertension than those with severe preeclampsia. These findings are consistent with similar studies

Table 3. Predictors of changes in persistent hypertension^a over six months postpartum among women previously diagnosed with preeclampsia.

Variable	Crude odds ratio (95% CI)	p-value	Adjusted odds ratio (95% CI)	p-value
HIV serostatus				
Negative	Ref	0.064	Ref	0.019
positive	1.25(0.99–1.58)		1.68 (1.09–2.60)	
Age years				
< 30	Ref	0.195	Ref	0.689
30–39	1.16(0.92–1.45)	0.332	0.91(0.59–1.41)	0.404
40 or more	1.38 (0.72–2.63)		0.62 (0.20–1.90)	
Marital status				
Unmarried	Ref	0.258		
Married	1.17(0.77–1.78)			
Education				
Primary/no education	Ref	0.855		
Secondary/Tertiary	1.04(0.71–1.53)			
Wealth index				
Poorest/poorer/middle	Ref	0.127		
Richer/richest	0.77(0.56–1.07)			
Depression and anxiety				
No	Ref	<0.001	Ref	0.001
yes	2.54(1.80–3.57)		2.06 (1.35–3.14)	
Onset of preeclampsia				
Early (<34 weeks)	Ref	0.074		
Late (>/ = 34 weeks)	1.22(0.98–1.53)			
Severity of Preeclampsia				
Severe	Ref	0.026	0.37 (0.16–0.85)	0.019
Mild/Moderate	0.52(0.28–0.97)			
Pregnancy outcomes				
Live/term birth	Ref	0.940		
Still/Preterm birth	1.01(0.72–1.43)			
Parity	1.15(1.04–1.27)	0.002	1.24 (1.07–1.45)	0.005
Food insecurity score	1.09(1.01–1.18)	0.032	1.11 (0.97–1.26)	0.110
Contraceptive use				
Other ^b	Re	0.421		
Intrauterine/other	1.14(0.64–2.04)	0.403		
Hormonal	1.25(0.86–1.82)			
Body mass index kg/m ²	1.02(1.01–1.05)	0.035	1.03(0.99–1.06)	0.086
Time since delivery (months)	0.49 (0.43–0.54)	<0.001	0.51(0.46–0.57)	<0.001

^aOutcome variable for the regression model (SBP>140 &/or DBP>90 coded/treatment: yes = 1, no = 0)

^b(sterilization, lactational amenorrhea, withdrawal, fertility awareness-based methods or dual methods), adjustment variables (body mass index, age, anxiety&depression, parity, food insecurity score, severity of preeclampsia), boldface indicates statistical significance at alpha less than 0.05.

<https://doi.org/10.1371/journal.pone.0309915.t003>

from high-income countries [55, 56]. Berks and colleagues [55] demonstrated that time to resolution of hypertension postpartum in women with diagnosed preeclampsia during pregnancy increased by 1.6-fold for every 10-mm Hg increase in maximal systolic blood pressure. Additionally, a systematic review and meta-analysis showed that the risk of future hypertension later in life increased by 6.7-fold among women with severe preeclampsia [56]. The link is thought to be through the extent of endothelial dysfunction, end organ damage and elevated biomarkers of inflammation [57]. The degree of damage to the systemic organs could affect the recovery from preeclampsia.

There was a relationship between increased parity and odds of persistent hypertension. Prior studies conducted in sub-Saharan Africa and high-income countries have reported inconsistent results [44, 58]. A study by Olagbuji and colleagues in Nigeria found no evidence

of an association [44]. Our study findings align with Lykke and colleagues from Denmark, who demonstrated that women with two or more pregnancies had 4.34-fold higher rates of persistent hypertension [58]. It is unclear the mechanism behind the observed association. It could be because of pregnancy's stress on the cardiovascular system, especially in women with a history of hypertensive disorders [59]. The body undergoes significant changes during pregnancy to support the growing fetus [60]. In women with multiparity, this cumulative cardiovascular stress can contribute to a higher risk of persistent hypertension after giving birth and in years to come [61].

There is a lack of studies exploring the link between anxiety, depression and persistent hypertension in women previously diagnosed with pre-eclampsia. A systematic review of studies from LMICs reported an association between food insecurity and depression in the general population [62] and similar findings have been reported among pregnant women in Ethiopia and Uganda [63–65]. It is plausible that the same underlying drivers that lead to persistent hypertension may simultaneously underpin anxiety and depression, including economic instability, housing insecurity, or exposure to violence [66]. Our findings add to this growing literature by identifying the link between anxiety, depression and persistent hypertension in postpartum women after preeclampsia.

Postpartum care for women living with HIV should consider long-term cardiovascular risk assessment before discharge from the hospital. This is important, particularly in LMICs that share a disproportionate burden of hypertension and HIV. The risk for each individual should determine the length of postpartum follow-up based on the assessment, which should include family history and cardiovascular risk scores.

Strengths and limitations

This is among the first studies to explore persistent hypertension after preeclamptic pregnancies in a high HIV prevalence setting. If confirmed by other studies, postpartum monitoring may serve as an early entry point for long-term hypertensive care among high-risk individuals. However, these findings should be interpreted in the context of some limitations. We could not assess the independent effect of ART since all women living with HIV were on ART. Furthermore, even though most similar studies have a shorter follow-up, six months may be too short for cardiovascular events to be observed. Therefore, there is a need for studies with a longer follow-up period to examine how hypertension resolves in this population and the independent effect of ART.

Conclusion

We found an elevated risk of persistent hypertension among participants living with HIV on ART. Peripartum patients in HIV-endemic settings may benefit from timely detection and treatment interventions to improve health outcomes. Timely detection and treatment of persistent hypertension could have lasting impacts on maternal health.

Supporting information

S1 Checklist. Strobe checklist.
(PDF)

S2 Checklist. Inclusivity in global research.
(PDF)

S3 Checklist. PLOOne_human_subjects_research_checklist_MM.
(PDF)

S1 Data set. Data set used for the study findings.

(CSV)

S1 File.

(DOCX)

S2 File. Questionnaires.

(PDF)

Acknowledgments

The study team acknowledges the contribution of the study participants, the University of North Carolina-University of Zambia-Wits Partnership for HIV and Women's Reproductive Health and the Partnership to Enhance Technical Support for Analytical Capacity and Data Use. We appreciate Dr Kalungia A. Chichoni and Dr Patrick Kaonga who helped review and edit the manuscript drafts. We also thank the research assistant Agatha Kalenshi, for the administrative work. In addition, we wish to thank the nurse research assistants, Ms Yvonne Tompwe and Ms Rozario Lukupa

Author Contributions

Conceptualization: Moses Mukosha, Abigail Hatcher, Benjamin H. Chi, Wilbroad Mutale.

Data curation: Moses Mukosha, Innocent Maposa.

Formal analysis: Moses Mukosha, Abigail Hatcher, Innocent Maposa.

Funding acquisition: Benjamin H. Chi.

Investigation: Moses Mukosha, Mwansa Ketty Lubeya.

Methodology: Moses Mukosha, Mwansa Ketty Lubeya, Innocent Maposa, Benjamin H. Chi, Wilbroad Mutale.

Project administration: Moses Mukosha, Mwansa Ketty Lubeya.

Resources: Abigail Hatcher, Benjamin H. Chi, Wilbroad Mutale.

Software: Moses Mukosha.

Supervision: Abigail Hatcher, Innocent Maposa, Benjamin H. Chi, Wilbroad Mutale.

Validation: Abigail Hatcher, Mwansa Ketty Lubeya, Innocent Maposa, Benjamin H. Chi, Wilbroad Mutale.

Visualization: Abigail Hatcher, Wilbroad Mutale.

Writing – original draft: Moses Mukosha.

Writing – review & editing: Moses Mukosha, Abigail Hatcher, Mwansa Ketty Lubeya, Innocent Maposa, Benjamin H. Chi, Wilbroad Mutale.

References

1. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. *Nature Reviews Nephrology*. 2020;1–15.
2. Magee LA, Brown MA, Hall DR, Gupte S, Hennessy A, Karumanchi SA, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. *Pregnancy hypertension*. 2022; 27:148–69.

3. Gómez-Olivé FX, Ali SA, Made F, Kyobutungi C, Nonterah E, Micklesfield L, et al. Regional and sex differences in the prevalence and awareness of hypertension: an H3Africa AWI-Gen study across 6 sites in sub-Saharan Africa. *Global heart*. 2017; 12(2):81–90. <https://doi.org/10.1016/j.gheart.2017.01.007> PMID: 28302553
4. Kintu A. The Impact of HIV and Antiretroviral Therapy on Cardiovascular Diseases in Sub-Saharan Africa 2020.
5. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension global hypertension practice guidelines. *Hypertension*. 2020; 75(6):1334–57. <https://doi.org/10.1161/HYPERTENSIONAHA.120.15026> PMID: 32370572
6. Organization WH. Global report on hypertension: the race against a silent killer. 2023.
7. Veiga ECdA Rocha PRH, Caviola LL Cardoso VC, Costa FdS Saraiva MdCP, et al. Previous pre-eclampsia and its association with the future development of cardiovascular diseases: a systematic review and meta-analysis. *Clinics*. 2021; 76.
8. Nakimuli A, Elliott AM, Kaleebu P, Moffett A, Mirembe F. Hypertension persisting after pre-eclampsia: a prospective cohort study at Mulago Hospital, Uganda. *PloS one*. 2013; 8(12):e85273. <https://doi.org/10.1371/journal.pone.0085273> PMID: 24392003
9. Ishaku SM, Jamilu T, Innocent AP, Gbenga KA, Lamarin D, Lawal O, et al. Persistent Hypertension Up to One Year Postpartum among Women with Hypertensive Disorders in Pregnancy in a Low-Resource Setting: A Prospective Cohort Study. *Global heart*. 2021; 16(1).
10. Cunningham Jr MW, LaMarca B. Risk of cardiovascular disease, end-stage renal disease, and stroke in postpartum women and their fetuses after a hypertensive pregnancy. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology*. 2018; 315(3):R521–R8. <https://doi.org/10.1152/ajpregu.00218.2017> PMID: 29897824
11. Dall'Asta A, D'Antonio F, Saccone G, Buca D, Mastantuoni E, Liberati M, et al. Cardiovascular events following pregnancies complicated by preeclampsia with emphasis on the comparison between early and late onset forms: a systematic review and meta-analysis. *Ultrasound Obstet Gynecol*. 2020. Epub 2020/06/03. <https://doi.org/10.1002/uog.22107> PMID: 32484256.
12. Adams JW, Watts DH, Phelps BR. A systematic review of the effect of HIV infection and antiretroviral therapy on the risk of pre-eclampsia. *International Journal of Gynecology & Obstetrics*. 2016; 133(1):17–21.
13. Black MH, Zhou H, Sacks DA, Dublin S, Lawrence JM, Harrison TN, et al. Hypertensive disorders first identified in pregnancy increase risk for incident prehypertension and hypertension in the year after delivery. *Journal of hypertension*. 2016; 34(4):728–35. <https://doi.org/10.1097/HJH.0000000000000855> PMID: 26809018
14. Olagbuji B, Ezeanochie M, Ande A, Okonkwo C. Prevalence and risk factors for persistent hypertension after the puerperium in pregnancies complicated with hypertensive disorders. *Journal of Obstetrics and Gynaecology*. 2012; 32(6):529–32. <https://doi.org/10.3109/01443615.2012.689891> PMID: 22779954
15. Duprez DA, Neuhaus J, Kuller LH, Tracy R, Bellosso W, De Wit S, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. *PloS one*. 2012; 7(9). <https://doi.org/10.1371/journal.pone.0044454> PMID: 22970224
16. Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD, et al. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. *Journal of the American Heart Association*. 2014; 3(3):e000844. <https://doi.org/10.1161/JAHA.114.000844> PMID: 24870935
17. Hemkens LG, Bucher HC. HIV infection and cardiovascular disease. *European heart journal*. 2014; 35(21):1373–81. <https://doi.org/10.1093/eurheartj/ehu528> PMID: 24408888
18. Hsue PY. Mechanisms of cardiovascular disease in the setting of HIV infection. *Canadian Journal of Cardiology*. 2019; 35(3):238–48. <https://doi.org/10.1016/j.cjca.2018.12.024> PMID: 30825947
19. Pillay P, Moodley K, Vatish M, Moodley J, Duarte R, Mackraj I. Exosomal Th1/Th2 cytokines in pre-eclampsia and HIV-positive preeclamptic women on highly active anti-retroviral therapy. *Cytokine*. 2020; 125:154795. <https://doi.org/10.1016/j.cyto.2019.154795> PMID: 31398625
20. Naicker T, Govender N, Abel T, Naidoo N, Moodley M, Pillay Y, et al. HIV associated preeclampsia: a multifactorial appraisal. *International Journal of Molecular Sciences*. 2021; 22(17):9157. <https://doi.org/10.3390/ijms22179157> PMID: 34502066
21. Premkumar A, Dude AM, Haddad LB, Yee LM. Combined antiretroviral therapy for HIV and the risk of hypertensive disorders of pregnancy: a systematic review. *Pregnancy hypertension*. 2019; 17:178–90. <https://doi.org/10.1016/j.preghy.2019.05.015> PMID: 31487638

22. Wimalasundera R, Larbalestier N, Smith J, De Ruiter A, Thom SM, Hughes A, et al. Pre-eclampsia, anti-retroviral therapy, and immune reconstitution. *The Lancet*. 2002; 360(9340):1152–4. [https://doi.org/10.1016/S0140-6736\(02\)11195-0](https://doi.org/10.1016/S0140-6736(02)11195-0) PMID: 12387967
23. Naicker T, Phoswa WN, Onyangunga OA, Gathiram P, Moodley J. Angiogenesis, Lymphangiogenesis, and the Immune Response in South African Preeclamptic Women Receiving HAART. *International journal of molecular sciences*. 2019; 20(15):3728. <https://doi.org/10.3390/ijms20153728> PMID: 31366152
24. Boyajian T, Shah PS, Murphy KE. Risk of preeclampsia in HIV-positive pregnant women receiving HAART: a matched cohort study. *Journal of Obstetrics and Gynaecology Canada*. 2012; 34(2):136–41. [https://doi.org/10.1016/S1701-2163\(16\)35156-8](https://doi.org/10.1016/S1701-2163(16)35156-8) PMID: 22340062
25. Phoswa WN, Naicker T, Ramsuran V, Moodley J. Pre-eclampsia: the role of highly active antiretroviral therapy and immune markers. *Inflammation Research*. 2019; 68(1):47–57. <https://doi.org/10.1007/s00011-018-1190-3> PMID: 30276649
26. Practice ACoO. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*. 2002; 77(1):67.
27. Vandenbroucke JP, Elm Ev, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Annals of internal medicine*. 2007; 147(8):W-163-W-94.
28. Mukosha M, Vwalika B, Lubeya MK, Kumwenda A, Kaonga P, Jacobs C, et al. Determinants and neonatal outcomes of preeclampsia among women living with and without HIV at a tertiary hospital in Zambia: a review of medical records. *The Pan African Medical Journal*. 2022;43.
29. Ngene NC, Moodley J. Blood pressure measurement in pregnancy and in hypertensive disorders of pregnancy: devices, techniques and challenges. *Cardiovasc J Afr*. 2019; 30(2):120–9. Epub 2019/02/06. <https://doi.org/10.5830/CVJA-2018-067> PMID: 30720845.
30. Health ZMo Health ZMo. Zambia consolidated guidelines for the treatment and prevention of HIV infection. The Ministry of Health and Ministry of Community Development, Mother and ...; 2014.
31. Chi BH, Musonda P, Lembalemba MK, Chintu NT, Gartland MG, Mulenga SN, et al. Universal combination antiretroviral regimens to prevent mother-to-child transmission of HIV in rural Zambia: a two-round cross-sectional study. *Bulletin of the World Health Organization*. 2014; 92:582–92. <https://doi.org/10.2471/BLT.13.129833> PMID: 25177073
32. Mo Health. Consolidated Guidelines for Treatment and Prevention of HIV Infection. Ministry of Health Lusaka, Zambia; 2014.
33. Chilambe M, Kalungia AC, Mangani A, Munkombwe Z. An analysis of pharmacovigilance case reports of adverse drug events attributable to dolutegravir-based antiretroviral treatment for HIV in Zambia. *Medical Journal of Zambia*. 2019; 46(4):305–13.
34. Swindale A, Bilinsky P. Development of a universally applicable household food insecurity measurement tool: process, current status, and outstanding issues. *The Journal of nutrition*. 2006; 136(5):1449S–52S. <https://doi.org/10.1093/jn/136.5.1449S> PMID: 16614442
35. Chakraborty NM, Fry K, Behl R, Longfield K. Simplified asset indices to measure wealth and equity in health programs: a reliability and validity analysis using survey data from 16 countries. *Global Health: Science and Practice*. 2016; 4(1):141–54.
36. Markova AD, Hadži-Lega M, Mijakoski D. Indicators of Moderate and Severe Preeclampsia in Correlation with Maternal IL10. *Open Access Maced J Med Sci*. 2016; 4(2):236–42. Epub 2016/06/24. <https://doi.org/10.3889/oamjms.2016.047> PMID: 27335593; PubMed Central PMCID: PMC4908738.
37. Erez O, Romero R, Maymon E, Chaemsathong P, Done B, Pacora P, et al. The prediction of late-onset preeclampsia: Results from a longitudinal proteomics study. *PLoS One*. 2017; 12(7):e0181468. Epub 2017/07/25. <https://doi.org/10.1371/journal.pone.0181468> PMID: 28738067; PubMed Central PMCID: PMC5524331.
38. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta psychiatrica scandinavica*. 1983; 67(6):361–70. <https://doi.org/10.1111/j.1600-0447.1983.tb09716.x> PMID: 6880820
39. Baker JV, Hullsiek KH, Engen NW, Nelson R, Chetchotisakd P, Gerstoft J, et al., editors. Early antiretroviral therapy at high CD4 counts does not improve arterial elasticity: a substudy of the strategic timing of antiretroviral treatment (START) trial. *Open forum infectious diseases*; 2016: Oxford University Press US.
40. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. Role of the T cell in the genesis of angiotensin II-induced hypertension and vascular dysfunction. *The Journal of experimental medicine*. 2007; 204(10):2449–60. <https://doi.org/10.1084/jem.20070657> PMID: 17875676

41. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, et al. Inflammation, immunity, and hypertension. *Hypertension*. 2011; 57(2):132–40. <https://doi.org/10.1161/HYPERTENSIONAHA.110.163576> PMID: 21149826
42. Masenga SK, Elijovich F, Koethe JR, Hamooya BM, Heimbürger DC, Munsaka SM, et al. Hypertension and metabolic syndrome in persons with HIV. *Current hypertension reports*. 2020; 22:1–8.
43. Hauspurg A, Countouris ME, Jeyabalan A, Hubel CA, Roberts JM, Schwarz EB, et al. Risk of hypertension and abnormal biomarkers in the first year postpartum associated with hypertensive disorders of pregnancy among overweight and obese women. *Pregnancy hypertension*. 2019; 15:1–6. <https://doi.org/10.1016/j.preghy.2018.10.009> PMID: 30825904
44. Olagbuji B, Ezeanochie M, Ande A, Okonkwo C. Prevalence and risk factors for persistent hypertension after the puerperium in pregnancies complicated with hypertensive disorders. *J Obstet Gynaecol*. 2012; 32(6):529–32. Epub 2012/07/12. <https://doi.org/10.3109/01443615.2012.689891> PMID: 22779954.
45. Xu Y, Chen X, Wang K. Global prevalence of hypertension among people living with HIV: a systematic review and meta-analysis. *Journal of the American Society of Hypertension*. 2017; 11(8):530–40. <https://doi.org/10.1016/j.jash.2017.06.004> PMID: 28689734
46. Mave V, Erlandson KM, Gupte N, Balagopal A, Asmuth DM, Campbell TB, et al. Inflammation and change in body weight with antiretroviral therapy initiation in a multinational cohort of HIV-infected adults. *The Journal of infectious diseases*. 2016; 214(1):65–72. <https://doi.org/10.1093/infdis/jiw096> PMID: 26962236
47. Powell-Wiley TM, Poirier P, Burke LE, Després J-P, Gordon-Larsen P, Lavie CJ, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*. 2021; 143(21):e984–e1010. <https://doi.org/10.1161/CIR.0000000000000973> PMID: 33882682
48. George S, McGrath N, Oni T. The association between a detectable HIV viral load and non-communicable diseases comorbidity in HIV positive adults on antiretroviral therapy in Western Cape, South Africa. *BMC infectious diseases*. 2019; 19:1–11.
49. Masenga SK, Hamooya BM, Nzala S, Kwenda G, Heimbürger DC, Mutale W, et al. Patho-immune mechanisms of hypertension in HIV: a systematic and thematic review. *Current hypertension reports*. 2019; 21:1–19. <https://doi.org/10.1007/s11906-019-0956-5> PMID: 31165257
50. Kaze FF, Njukeng FA, Kengne A-P, Ashuntantang G, Mbu R, Halle MP, et al. Post-partum trend in blood pressure levels, renal function and proteinuria in women with severe preeclampsia and eclampsia in Sub-Saharan Africa: A 6-months cohort study. *BMC pregnancy and childbirth*. 2014; 14(1):1–7. <https://doi.org/10.1186/1471-2393-14-134> PMID: 24712704
51. Osoti AO, Page ST, Richardson BA, Guthrie BL, Kinuthia J, Polyak SJ, et al. Postpartum metabolic syndrome and high-sensitivity C-reactive protein after gestational hypertension and pre-eclampsia. *International Journal of Gynecology & Obstetrics*. 2020; 151(3):443–9.
52. Girsberger M, Muff C, Hösli I, Dickenmann MJ. Short term sequelae of preeclampsia: a single center cohort study. *BMC pregnancy and childbirth*. 2018; 18(1):1–7.
53. Boucheron P, Lailler G, Moutengou E, Regnault N, Gabet A, Deneux-Tharaux C, et al. Hypertensive disorders of pregnancy and onset of chronic hypertension in France: the nationwide CONCEPTION study. *European Heart Journal*. 2022; 43(35):3352–61. <https://doi.org/10.1093/eurheartj/ehab686> PMID: 34643681
54. Suzuki H, Watanabe Y, Arima H, Kobayashi K, Ohno Y, Kanno Y. Short-and long-term prognosis of blood pressure and kidney disease in women with a past history of preeclampsia. *Clinical and experimental nephrology*. 2008; 12:102–9. <https://doi.org/10.1007/s10157-007-0018-1> PMID: 18180874
55. Berks D, Steegers EA, Molas M, Visser W. Resolution of hypertension and proteinuria after preeclampsia. *Obstetrics & Gynecology*. 2009; 114(6):1307–14.
56. Sukmanee J, Liabsuetrakul T. Risk of future cardiovascular diseases in different years postpartum after hypertensive disorders of pregnancy: A systematic review and meta-analysis. *Medicine*. 2022; 101(30). <https://doi.org/10.1097/MD.00000000000029646> PMID: 35905265
57. Parthasarathy S, Soundararajan P, Sakthivelu M, Karupiah KM, Velusamy P, Gopinath SC, et al. The role of prognostic biomarkers and their implications in early detection of preeclampsia: A systematic review. *Process Biochemistry*. 2023.
58. Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. *Hypertension*. 2009; 53(6):944–51. <https://doi.org/10.1161/HYPERTENSIONAHA.109.130765> PMID: 19433776
59. Sava RI, March KL, Pepine CJ. Hypertension in pregnancy: Taking cues from pathophysiology for clinical practice. *Clinical cardiology*. 2018; 41(2):220–7. <https://doi.org/10.1002/clc.22892> PMID: 29485737

60. Morris EA, Hale SA, Badger GJ, Magness RR, Bernstein IM. Pregnancy induces persistent changes in vascular compliance in primiparous women. *American journal of obstetrics and gynecology*. 2015; 212(5):633. e1-. e6. <https://doi.org/10.1016/j.ajog.2015.01.005> PMID: 25576820
61. Coutinho T, Lamai O, Nerenberg K. Hypertensive disorders of pregnancy and cardiovascular diseases: current knowledge and future directions. *Current Treatment Options in Cardiovascular Medicine*. 2018; 20:1–11.
62. Smith L, Sánchez GFL, Oh H, Rahmati M, Tully M, Yon DK, et al. Association between food insecurity and depressive symptoms among adolescents aged 12–15 years from 22 low-and middle-income countries. *Psychiatry Research*. 2023:115485. <https://doi.org/10.1016/j.psychres.2023.115485> PMID: 37729716
63. Dibaba Y, Fantahun M, Hindin MJ. The association of unwanted pregnancy and social support with depressive symptoms in pregnancy: evidence from rural Southwestern Ethiopia. *BMC pregnancy and childbirth*. 2013; 13(1):1–8. <https://doi.org/10.1186/1471-2393-13-135> PMID: 23800160
64. Jebena MG, Taha M, Nakajima M, Lemieux A, Lemessa F, Hoffman R, et al. Household food insecurity and mental distress among pregnant women in Southwestern Ethiopia: a cross sectional study design. *BMC pregnancy and childbirth*. 2015; 15:1–9.
65. Natamba BK, Mehta S, Achan J, Stoltzfus RJ, Griffiths JK, Young SL. The association between food insecurity and depressive symptoms severity among pregnant women differs by social support category: a cross-sectional study. *Maternal & child nutrition*. 2017; 13(3):e12351. <https://doi.org/10.1111/mcn.12351> PMID: 27507230
66. KYU TDBH. THE PREVALENCE OF HOUSEHOLD FOOD INSECURITY AND IT'S ASSOCIATION WITH HYPERTENSION AND OTHER CORRELATES AMONG ADULTS IN ARUA MUNICIPALITY: A CROSS-SECTIONAL STUDY: MAKERERE UNIVERSITY.